BioSpace News Archive

Ascentage Pharma (6855.HK) announced that the results from a Phase I and Phase II study of olverembatinib (HQP1351) for the treatment of chronic myeloid leukemia (CML) have recently been published in the renowned oncology journal, the Journal of Hematology & Oncology (JHO), further demonstrating the durable efficacy and safety of olverembatinib in patients with CML.

The latest market analysis report published by Reports and Data, titled ‘Global Ductal Carcinoma in Situ Market – Forecast to 2030,’ thoroughly examines the Ductal Carcinoma in Situ industry to provide essential data & information for the targeted readers.

SOLVE FSHD announced an investment of US$3 million in Altay Therapeutics; a company focused on developing lifesaving therapies by targeting disease-causing transcription factors.

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.

The global hydralazine market is expected to grow at a CAGR of 3.5% during the forecast period. The rising prevalence of hypertension and heart diseases is the major factor driving the growth of this market.

The global viral vector & plasmid manufacturing market size reached USD 517.4 Million in 2021 and is expected to register a revenue CAGR of 14.3% during the forecast period, according to the latest analysis by Emergen Research.

The global predictive biomarkers market is expected to register a steady revenue CAGR during the forecast period, according to the latest analysis by Emergen Research.

Marius Pharmaceuticals, a patient-centric healthcare company, announced the approval of KYZATREX™ by the U.S. Food and Drug Administration.

The latest market analysis report published by Reports and Data, titled ‘Global Staphylococcus Infection Market – Forecast to 2030,’ thoroughly examines the Staphylococcus Infection industry to provide essential data & information for the targeted readers.

Villepinte, Wednesday, September 21, 2022: Guerbet, a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated results for the first half of 2022.